🇺🇸 FDA

Intelligence · Clinical Pipeline

GSK Glaxo Smith Pipeline

All ClinicalTrials.gov programs at GSK Glaxo Smith — phase, modality, and trial IDs.

Programs
34

Quick answer

GSK Glaxo Smith has 34 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 50mg Ezogabine/retigabine

    GlaxoSmithKline

    Epilepsy

    phase 1 small molecule completed

    1 trial

  2. A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  3. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  4. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  5. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

    GlaxoSmithKline

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  6. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  7. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  8. A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9)

    GlaxoSmithKline

    Multiple Myeloma

    phase 1 other active

    1 trial

  9. A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 other active

    1 trial

  10. A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  11. A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-134a (reference) in healthy participants aged 18 to 55 inclusive.

    GlaxoSmithKline

    Healthy volunteers

    phase 1 other active

    1 trial

  12. A study to compare the relative potency of salbutamol administered via metered dose inhalers containing propellants HFA-152a to HFA-134a in mild asthmatics aged 18 to 65 inclusive.

    GlaxoSmithKline

    Mild Asthma

    phase 1 other active

    1 trial

  13. A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.

    GlaxoSmithKline

    Kidney Disease

    phase 1 other active

    1 trial

  14. A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female participants of non-childbearing potential aged 18 to 65 years of age

    GlaxoSmithKline

    Tuberculosis

    phase 1 other active

    1 trial

  15. A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  16. A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 other active

    1 trial

  17. A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  18. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  19. Chloroquine

    GlaxoSmithKline

    Malaria

    phase 1 small molecule completed

    1 trial

  20. Daprodustat 2 mg tablet

    GlaxoSmithKline

    Anaemia

    phase 1 small molecule completed

    1 trial

  21. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  22. GSK2269557 ELLIPTA DPI

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  23. GSK2879552

    GlaxoSmithKline

    Leukaemia, Myelocytic, Acute

    phase 1 small molecule terminated

    1 trial

  24. GSK525762

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule terminated

    1 trial

  25. GSK5533524

    GlaxoSmithKline

    Neoplasms

    phase 1 small molecule active

    1 trial

  26. Lamivudine

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  27. New formulation

    GlaxoSmithKline

    Herpes Labialis

    phase 1 small molecule completed

    1 trial

  28. Pazopanib

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 1 small molecule completed

    1 trial

  29. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  30. Poliorix

    GlaxoSmithKline

    Poliomyelitis

    phase 1 mab completed

    1 trial

  31. Prednisolone

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  32. SB-659032

    GlaxoSmithKline

    Atherosclerosis

    phase 1 small molecule completed

    1 trial

  33. Test Montelukast

    GlaxoSmithKline

    Respiratory Disorders

    phase 1 small molecule completed

    1 trial

  34. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does GSK Glaxo Smith have?

34 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.